Research programme: protein therapeutics - Epistem

Drug Profile

Research programme: protein therapeutics - Epistem

Alternative Names: EPI-2221; EPI-288; EPI-3905; EPI-6

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Epistem
  • Class Peptides; Proteins; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer; Gastrointestinal disorders

Highest Development Phases

  • No development reported Cancer; Gastrointestinal disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom
  • 23 Sep 2010 Research programme: protein therapeutics - Epistem is available for licensing http://www.epistem.co.uk/default.asp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top